Search

Your search keyword '"A. Wahner"' showing total 3,152 results

Search Constraints

Start Over You searched for: Author "A. Wahner" Remove constraint Author: "A. Wahner"
3,152 results on '"A. Wahner"'

Search Results

101. A phase 1 and pharmacodynamic study of chronically-dosed, single-agent veliparib (ABT-888) in patients with BRCA1- or BRCA2-mutated cancer or platinum-refractory ovarian or triple-negative breast cancer

102. Combined PARP and HSP90 inhibition: preclinical and Phase 1 evaluation in patients with advanced solid tumours

103. Effect of Aromatherapy on Perceived Mental Health Parameters for Academic Department Workers Working From Home During the COVID-19 Pandemic: A Pilot Study.

107. A Phase I trial of Nab-Paclitaxel/Bevacizumab (AB160) Nano-Immunoconjugate Therapy for Gynecologic Malignancies

110. An integrated precision medicine approach in major depressive disorder: a study protocol to create a new algorithm for the prediction of treatment response

114. New MARTA Five Points Project Approved

115. The Essential Role for Laboratory Studies in Atmospheric Chemistry

116. Ubiquitous atmospheric production of organic acids mediated by cloud droplets

118. Randomized Phase II Study of Gemcitabine With or Without ATR Inhibitor Berzosertib in Platinum-Resistant Ovarian Cancer: Final Overall Survival and Biomarker Analyses.

119. NRG‐GY012: Randomized phase 2 study comparing olaparib, cediranib, and the combination of cediranib/olaparib in women with recurrent, persistent, or metastatic endometrial cancer.

120. Impact of HO2/RO2 ratio on highly oxygenated α-pinene photooxidation products and secondary organic aerosol formation potential.

121. Effects of COVID-19 pandemic on mental health of children and adolescents: A systematic review of survey studies

122. Berzosertib plus gemcitabine versus gemcitabine alone in platinum-resistant high-grade serous ovarian cancer: a multicentre, open-label, randomised, phase 2 trial

125. NRG‐GY012: Randomized phase 2 study comparing olaparib, cediranib, and the combination of cediranib/olaparib in women with recurrent, persistent, or metastatic endometrial cancer

126. Ozone pollution mitigation strategy informed by long-term trends of atmospheric oxidation capacity

128. PR062/#686 First-in-human phase 1 study of torl-1–23, a novel claudin 6 (CLDN6) targeted antibody drug conjugate (ADC) in patients with ovarian cancer

132. A Replication stress biomarker is associated with response to gemcitabine versus combined gemcitabine and ATR inhibitor therapy in ovarian cancer

134. New shopping shuttles arrive for Residence Halls

135. Midterm season and construction at the library

136. The parking crisis during the first few weeks

137. Mysterious lockdown at Piedmont Central

138. Rising COVID-19 cases as students come back for the new semester

139. The effect of older age on treatment outcomes in women with advanced ovarian cancer receiving chemotherapy: An NRG-Oncology/Gynecologic Oncology Group (GOG-0182-ICON5) ancillary study

140. Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): a multicentre, open-label, single-arm, phase 2 trial

141. 53BP1 as a potential predictor of response in PARP inhibitor-treated homologous recombination-deficient ovarian cancer

142. The potential of drone observations to improve air quality predictions by 4D-var.

143. Impact of temperature-dependent non-PAN peroxynitrate formation, RO2NO2, on nighttime atmospheric chemistry.

144. Renal calyceal rupture with extensive urinoma formation as a complication of cervical cancer.

145. Phase 1 trial of navitoclax and sorafenib in patients with refractory solid tumors with a hepatocellular carcinoma expansion cohort.

150. Comparison of isoprene chemical mechanisms under atmospheric night-time conditions in chamber experiments: evidence of hydroperoxy aldehydes and epoxy products from NO3 oxidation

Catalog

Books, media, physical & digital resources